Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Comparison of DRL_TC, Actemra, and RoActemra in Healthy Volunteers
NCT04885829Phase 1Completed
- Sponsor
- Syneos Health
- Start
- May 2021
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of DRL_TC in rheumatoid arthritis (RA) and giant cell arteritis (GCA), sponsored by Syneos Health. Started May 2021; status: completed.
02
Drugs
DRL_TC
03
Conditions
rheumatoid arthritis (RA)giant cell arteritis (GCA)
Beyond the preview
Go deeper on NCT04885829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04885829.